Difference in glucose intolerance between C57BL/6J and ICR strain mice with streptozotocin/nicotinamide-induced diabetes

Biomedical Research

Volumn 33, Issue 1, 2012, Pages 63-66

  Shimizu, Ryo ^a   Sakazaki, Fumitoshi ^b   Okuno, Tomofumi ^b   Nakamuro, Katsuhiko ^b   Ueno, Hitoshi ^b  

^a HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; NICOTINAMIDE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSTITUTE FOR CANCER RESEARCH MOUSE; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; STRAIN DIFFERENCE; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NIACINAMIDE;

MUS;

EID: 84857770839     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.33.63     Document Type: Article

References (17)

1. Amos A, McCarty D and Zimmet P (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med 14, S1-S85.
2. Bell GI and Polonsky KS (2001) Diabetes mellitus and genetically programmed defects in β-cell function. Nature 414, 788-791.
3. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
4. Cardinal JW, Allan DJ and Cameron DP (1999) Poly(ADPribose) polymerase activation determines strain sensitivity to streptozotocin-induced β cell death in inbred mice. J Mol Endocrinol 22, 65-70.
5. Das SK and Chakrabarti R (2005) Non-insulin dependent diabetes mellitus: present therapies and new drug targets. Mini Rev Med Chem 5, 1019-1034.
6. Haughton CL, Dillehay DL and Lawrence SP (1999) Insulin replacement therapy for the rat model of streptozotocininduced diabetes mellitus. Lab Anim Sci 49, 639-645.
7. Hayashi K, Kojima R and Ito M (2006) Strain differences in the diabetogenic activity of streptozotocin in mice. Biol Pharm Bull 29, 1110-1119.
8. Ito M, Kondo Y, Nakatani A, Hayashi K and Naruse A (2001) Characterization of low dose streptozotocin-induced progressive diabetes in mice. Environ Toxicol Pharmacol 9, 71-78.
9. King H, Aubert R and Herman R (1998) Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 21, 1414-1431.
10. Like AA and Rossini AA (1976) Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193, 415-417.
11. Nakamura T, Terajima T, Ogata T, Ueno K, Hashimoto N, Ono K and Yao S (2006) Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozoocin and nicotinamide. Biol Pharm Bull 29, 1167-1174.
12. Rossini AA, Appel MC, Williams RM and Like AA (1977) Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes 26, 916-920.
13. Scarpelli DG (1989) Toxicology of the pancreas. Toxicol Appl Pharmacol 101, 543-554.
14. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50, 536-546.
15. Tripathi BK and Srivastava AK (2006) Complications and therapeutics. Med Sci Monit 12, 130-147.
16. Uchigawa Y, Yamamoto H, Kawamura A and Okamoto H (1982) Protection by superoxide dismutase, catalase, and poly (ADP-ribose) synthetase inhibitors against alloxan-and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. J Biol Chem 257, 6084-6088.
17. Wei M, Gaskill SP, Haffner SM and Stern MP (1998) Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Study. Diabetes Care 7, 1167-1172.